Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Suven Life Sciences has received three new Australian patents 2003237599, 2005335620 and 2006305502 corresponding to three new chemical entities (Necks), from Australian Patent Office.
Subscribe to our email newsletter
The new patents are for the treatment of disorders associated with neurodegenarative diseases and these patents are valid until 2022, 2025 and 2025 respectively.
Suven Life Sciences said that with these new patents it has total of 7 granted Australian patents on Necks.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s, ADHA, Parkinson, Schizophrenia and Hunting ton’s diseases.
Vena Jasti, CEO of Suven, said: “We are pleased by the grant of these three patents to Suven by Australian Patent office for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated $20bn market globally.”